Compare Gilead Sciences, Inc. (GILD) vs Pinterest Inc (PINS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Pinterest Inc — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while Pinterest Inc trades at $23.5 (market cap $13.26B). The key difference: Gilead Sciences, Inc. is far larger — about 12.3× Pinterest Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| GILD | PINS | |
|---|---|---|
Market Cap | $163.51B | $13.26B |
Sector | Health | Media |
52-Week High | $155.80 | $39.17 |
52-Week Low | $108.22 | $15.42 |
Enterprise Value | $178.05B | $13.17B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Pinterest (PINS) trades at $23.52, up 4.05% in the last session, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 EPS of $0.27, beating expectations, and maintains strong revenue growth, reaching $4.22B in 2025. Recent news highlights AI-driven shopping initiatives and user growth, with 631 million monthly active users in Q1 2026 (Zacks Investment Research, 2026-06-23).
The stock offers upside to the consensus price target of $27.53, with 54% of analysts rating it a buy. However, high valuation multiples (P/E of 49.33) and competitive pressures pose risks. Net cash flow turned negative in 2025, though operating cash flow remains robust at $1.28B, indicating underlying business strength amid investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
